Eris Lifesciences Ltd.
Listed
NSE & BSE
Mainboard
Live Chart
| Category | Subscription | Shares Offered | % of Total | Amount (₹Cr) |
|---|---|---|---|---|
|
QIB
|
Over 1.00x
|
21,543,750
74.61% |
74.61%
|
₹1,299.09 |
|
NII / HNI
|
Over 1.00x
|
4,308,750
14.92% |
14.92%
|
₹259.82 |
|
Retail
|
Over 1.00x
|
2,872,500
9.95% |
9.95%
|
₹173.21 |
|
Employees
|
Awaited |
150,000
0.52% |
0.52%
|
₹9.05 |
| Total | 1.00x | 28,875,000 |
100% | ₹1,741.16 |
| Category | Shares Offered | Amount (₹Cr) | Size (%) |
|---|---|---|---|
| QIB | 21,543,750 | ₹1,299.09 |
74.61%
|
| NII | 4,308,750 | ₹259.82 |
14.92%
|
| Retail | 2,872,500 | ₹173.21 |
9.95%
|
| Employee | 150,000 | ₹9.05 |
0.52%
|
| Total | 28,875,000 | ₹1,741.16 |
100.00%
|
| QIB | NII | Retail | Total | |||||
|---|---|---|---|---|---|---|---|---|
| Ex. Anchor | Anchor | Total QIB | Below ₹10L | Above ₹10L | Total NII | |||
| Allocation (shares) | — | — | — | — | — | 4,308,750 | 2,872,500 | 7,181,250 |
| Allotment price (₹) | 603 | 603 | 603 | 603 | 603 | 603 | 603 | 603 |
| No. of applications | — | — | — | — | — | — | — | — |
| No. of shares applied | — | — | — | — | — | — | — | — |
| Amount collected (₹Cr) | — | — | — | — | — | — | ₹173.21 | ₹173.21 |
| Times subscribed | 1 | — | — | — | — | 1 | 1 | 1 |
| Shares allotted | — | — | — | — | — | 4,308,750 | 2,872,500 | 7,181,250 |
| No. of allottees | — | — | — | — | — | — | — | — |
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min — 2 Lots) | 2 | 48 | ₹28,944 |
| Retail (Max — 13 Lots) | 13 | 312 | ₹188,136 |
| S-HNI (Min — 14 Lots) | 14 | 336 | ₹202,608 |
| B-HNI (Min — 70 Lots) | 70 | 1,680 | ₹1,013,040 |
Eris Lifesciences Ltd. is proposing an IPO on NSE & BSE under the Mainboard category. Total issue: 2,88,75,000 shares (aggregating up to ₹1,740.49 Cr).
Opens 16 Jun 2017, closes 20 Jun 2017. Listing: 29 Jun 2017. Apply via ASBA or UPI.
| Particulars | 31-Mar-16 | 31-Mar-15 | 31-Mar-14 |
|---|---|---|---|
| Revenue from Operations | 597.02 | 545.56 | 508.82 |
| EBITDA | N/A | N/A | N/A |
| Profit After Tax (PAT) | 134.86 | 89.26 | 70.91 |
| Net Worth | N/A | N/A | N/A |
| Total Assets | 397.36 | 357.29 | 270.60 |
| Reserves & Surplus | N/A | N/A | N/A |
| Borrowings | N/A | N/A | N/A |
| EBITDA Margin (%) | N/A | — | — |
| PAT Margin (%) | N/A | — | — |
Eris Lifesciences Ltd. IPO is subscribed 1.00 times by Jun 20, 2017. Retail: 1.00x. QIB: 1.00x. NII: 1.00x.
| Investor Category | Subscription |
|---|---|
| Qualified Institutional (QIB) | 1.00x |
| Non Institutional (NII/HNI) | 1.00x |
| Retail Individual | 1.00x |
| Total Subscription | 1.00x |
The Eris Lifesciences Ltd. IPO retail category is subscribed 1.00 times as of 20 Jun 2017. The retail portion is oversubscribed.
Subscribe via your broker app using ASBA or UPI. Opens 16 Jun 2017 and closes 20 Jun 2017. Min investment: ₹14,472 (1 lot = 24 shares). UPI mandate: 2017-06-20.
The Eris Lifesciences Ltd. IPO subscribed 1.00x overall. QIB: 1.00x, NII: 1.00x, Retail: 1.00x. Applications: from NSE/BSE.
Check allotment on the registrar website. Enter your PAN, application number or DP/Client ID. Allotment date: 26 Jun 2017. Refunds: on 27 Jun 2017.
The Eris Lifesciences Ltd. IPO listing date is 29 Jun 2017, Thursday. Listed on: NSE & BSE. Issue price: ₹603. Estimated listing: ₹603. GMP: NIL.
The Eris Lifesciences Ltd. IPO closes on 20 Jun 2017, Tuesday. UPI mandate: 2017-06-20. Allotment: 26 Jun 2017. Listing: 29 Jun 2017.